Synonyms: CM-082 | CM082 | Example 8 [WO2008033562A2] | EYP-1901 | X-82
Compound class:
Synthetic organic
Comment: Vorolanib (CM082) is a potent and selective, oral clinical stage multi-kinase inhibitor. Targets include all VEGFR isoforms, PDGFR and CSF1R. [1-3]. It is a structural derivative of sunitinib. Vorolanib has anti-angiogenic activity, and is being investigated for anti-tumour effects and utility to treat ocular neovascularisation.
|
|
No information available. |
Summary of Clinical Use |
CM082 has advanced to clinical evaluations in various types of solid tumours [4-5] and in age-related macular degeneration (wet AMD). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03710863 | Safety and Tolerability of Oral CM082 in Patients With wAMD | Phase 2 Interventional | AnewPharma | ||
NCT03848611 | CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). | Phase 2 Interventional | AnewPharma | ||
NCT04747197 | First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) | Phase 1 Interventional | EyePoint Pharmaceuticals, Inc. |